TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07289477: A Phase I/III Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Putamen Transplantation of NouvNeu001 Injection for Multiple System Atrophy

Sponsor: iRegene Therapeutics Co., Ltd. · Phase: PHASE1 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,416,496

Rescue Site Savings

+$5,567,024

Unlock Full NCT07289477 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07289477 Rescue Dossier →